CONVERGENCE
Pathology, Laboratory Diagnostics and Population Health
8TH ANNUAL
CLINICAL LAB 2.0 WORKSHOP
March 3-4, 2025 • Pendry Chicago
Project Santa Fe Foundation’s
2025 CL2.0 Workshop
CONVERGENCE
Join lab industry leaders to explore the convergence of pathology, laboratory diagnostics and population health.
A HIGH-TOUCH, HIGHLY INTERACTIVE, LIMITED SEATING EVENT
We invite you to discover the latest evidence supporting laboratories' role in population health and cost avoidance, learn the roadmap for transitioning your clinical lab, and gain valuable insights across two days of exclusive collaboration and networking with laboratory thought leaders.
The potential value of the clinical lab does not end at the time we release a result — rather that’s where it begins.
Join Us at the Hotel Pendry Chicago
Recently Michelin rated, steeped in history, anchored in style, and set within the iconic 1929 Art Deco Carbide & Carbon building in Chicago’s loop neighborhood, Pendry Chicago is a modern luxury hotel that pays homage to both the past and the present.
You will find Pendry Chicago’s interiors contemporary and comfortable, designed with an eye for the Carbide & Carbon building’s illustrious Art Deco heritage and combined with a modern vision of luxury hospitality.
2025 CL2.0 Workshop Agenda
Join the crucial conversation with fellow leaders across the industry as we define the future business model for the clinical laboratory. Represented at this workshop is a tremendously respected collective body of knowledge, take your seat at the table and make an important contribution as critical questions are addressed that will shape the future of our collective industry.
More details on speakers and sessions to follow!
Sunday, March 2, 2025
5:30pm – 7:30pm: Welcome Reception
Join us for laid back networking as we welcome everyone to the beautiful Pendry Chicago.
Monday, March 3, 2025
7am – 8am: Breakfast
ACTIVATING THE CONSUMER
8am – 8:15am: Welcome to the Crucial Conversation!
Khosrow Shotorbani, MT(ASCP)
President, and CEO, Project Santa Fe Foundation
8:15am – 8:45am: Clinical Lab 2.0 Health Equity: Health Equity Requires Translating Laboratory Medicine & Pathology’s Value Beyond Test Volumes
Octavia M. Peck Palmer, PhD
Vice Chair of Health Equity, Associate Professor of Pathology, University of Pittsburgh Medical Center
The future of laboratory medicine and pathology lies in extracting actionable insights from the sea of clinical data labs already generate. Only through the intelligent use of this data can the traditional focus on lab testing volumes be shifted to achieve health equity across diverse populations and to advance patient care. With this approach, trends are revealed, gaps in healthcare access are identified, and the development of innovative algorithms can be supported, addressing disparities in patient care and outcomes. This evolution is necessary to pave the way for equitable healthcare for all.
8:45am – 10am: Engage: Consumer Activation
Facilitator: Octavia M. Peck Palmer, PhD
Vice Chair of Health Equity, Associate Professor of Pathology, University of Pittsburgh Medical Center
Healthcare revolution is nigh, and the future of clinical laboratories is being redefined. The focus is shifting toward patient engagement and consumer activism, which are both crucial for fostering health equity. Traditional healthcare models have often overlooked the diverse needs of populations, making the transition to the Clinical Lab 2.0 model urgent, as it emphasizes empowering patients early in their healthcare journeys, transforming them from passive recipients to active advocates for their health. Panelists will highlight the importance of integrating actionable insights from clinical data to uncover disparities in healthcare access and outcomes. Addressing the aging population and the accompanying disease burden will be covered, as well as the significance of recognizing demographic determinants, funding fatigue, and chronic pandemics as critical factors influencing healthcare today. By fostering collaboration among pathology, lab management, and industry partners, clinical laboratories can evolve beyond mere test processing to play a vital role in achieving equitable healthcare. Through harnessing the power of patient engagement and consumer activation, a more equitable system where everyone receives the care they deserve can be achieved.
Role of the Consumer Driving Care
Cherise Shockley
Patient Advocate and Founder, Diabetes Social Media Advocacy
The Coming Healthcare Revolution
David W. Johnson
Chief Executive Officer, 4sight Health
Q&A and Group Discussion
FRAMING THE MOVEMENT
10:15am – 10:30am: Practicing Tomorrow’s Medicine—Clinical Lab 2.0 Driving "Transformational Care"
Myra Wilkerson, MD
Chair, Diagnostic Medicine Institute, Geisinger Health System
The future has arrived, but we haven’t yet aligned our healthcare with the value propositions of value-based care. Is anyone fully satisfied with the current “sick care” model? What does wellness care embody, and how can we shape the practice of tomorrow’s medicine today? This session will cover the roles laboratorians can play in transforming medicine from reactive confirmation to proactive, predictive whole-person care, as well as the industry partners we need to form and implement the building blocks to create a blueprint for shaping the future state of medicine.
10:30am – 12:15pm: Clinical Lab 2.0 Committees in Action
Facilitator: James Crawford, MD, PhD
Professor and Chair Emeritus, Department of Pathology and Laboratory Medicine, Northwell Health
Multi-Institutional Demonstration Projects
Kathleen Swanson, MS, RPh
Project Manager, Pillar 3 Demonstration Projects, Project Santa Fe Foundation
Business/Alternative Payment Model
Lena Chaihorsky
Senior Vice President, Payor Innovation, Alva10 Inc.
Richard VanNess, MS
Co-Founder, Wuscott, LLC
Pathology Informatics/Artificial Intelligence
Amjad Azizi
Director, Informatics Strategy and Solutions, Sysmex America
Ulysses G. J. Balis, MD, FCAP, FASCP
Associate Chief Medical Information Officer, University of Michigan
Education/Certification
Angela Sanchez, MD
Chief Medical Officer, TriCore
Nancy Stratton, MBA
Chief Executive Officer, COLA
Clinical Lab 2.0 Change Management: Dual Transformation
R. Keith Laughman, DBA
Founder & Managing Partner, Caretinuum Advisors
Q&A and Attendee Feedback/Crowdsourcing
12:15pm – 1:15pm: Networking Lunch
TRANSITIONING FROM REACTIVE CONFIRMATION TO PROACTIVE PREDICTION Part 1:
Healthcare Partnerships
1:15pm – 3:30pm: Transitioning from Reactive Confirmation to Proactive Prediction
Reengineering the laboratory from reactive confirmation to proactive prediction is essential. The Clinical Lab 2.0 model can serve as a catalyst to create new strategies, alternative payment models, and foster partnerships. In this session, experts will demonstrate how utilizing the currently dormant lab data assets can improve patient outcomes and create sustainable value. Key components needed to reengineer clinical laboratories’ future role by developing proactive prediction models and strategically planning for the labs’ quantifiable role in risk-based healthcare will be covered. Panelists will highlight disease prevalence, patient engagement, the role of the laboratory’s expertise, population health, measurements of outcome, and local, national, and international challenges.
Facilitator: Richard Zarbo, MD, DMD
System Chair, Henry Ford Health Pathology and Laboratory Medicine
National Kidney Foundation: Call to Action
Elizabeth Montgomery
VP, Learning Strategies, National Kidney Foundation
Clinical Lab 2.0 Playbook: Convergence of Diagnostics and Population Health
Kathleen Swanson, MS, RPh
Project Manager, Pillar 3 Demonstration Projects, Project Santa Fe Foundation
Clinical Lab 2.0 Initiated Population Health
Jennifer Houlihan, MSP
Vice President Enterprise Population Health, Advocate Health
Igniting the Power of Lab Medicine: Trends of Healthcare Excellence
Tricia Ravalico
Global Director Scientific Leadership and Education, Core Diagnostics
Executive Lead of UNIVANTS of Healthcare Excellence Program, Abbott
Future State Pathology Platform
Gaurav Sharma, MD
Vice Chair for Clinical Pathology, Henry Ford Health
Session Summation
TRANSITIONING FROM REACTIVE CONFIRMATION TO PROACTIVE PREDICTION - Part 2:
Industry Partnerships
3:45pm – 4pm: Clinical Lab 2.0 Demonstration Projects In Action
Nkem Okoye, PhD, DABCC
Director, Clinical Chemistry and Diagnostic Immunology, Northwell Health
Industry partners are critical to amplifying the Clinical Lab 2.0 mission and supporting the transformation from the current model of reactive confirmation to the future state of proactive prediction. This session will highlight how industry partners enable the transformation to begin practicing tomorrow’s medicine today.
4pm – 5:30pm: Clinical Lab 2.0 in Industry Partnership - Industry Enablement
Facilitator: Khosrow R. Shotorbani, MBA, MT(ASCP)
President, and CEO, Project Santa Fe Foundation
Alex Carterson, MD, PhD
Divisional Vice President of Abbott Medical, Abbott
Rodney Della Vedova
Director, North America Market Development, Beckman Coulter
Minkey Wungwattana, PharmD, BCIDP
Field Medical Director U.S., bioMerieux
Lily Li, PhD
Medical Safety Officer and Sr. Director of Medical, Scientific & Clinical Affairs, QuidelOrtho
Soham Shah, MD, MBA, CPE, FACP
Medical Director Digital Health, Roche Information Solutions
Melanie Pollan, PhD, MT(ASCP)
Sr. Director, Medical & Scientific Affairs, Siemens Healthineers
M.E. (Doc) de Baca, MD
VP Medical Affairs, Sysmex America, Inc.
Veena Joy, MSc, PhD
US Market Development and Strategy Lead, Thermo Fisher
5pm – 5:30pm: Q&A and Group Discussion
5:30pm – 7:30pm: Evening Reception
Tuesday, March 4, 2025
7am – 8am: Breakfast
8am – 8:15am: Welcome Back!
Mark Fung, MD, PhD
Vice Chair for Population Health, University of Vermont Health Network
8:15am – 9:15am: Transitioning of Lab 1.0 to Lab 2.0: Dual Transformation Continued
Khosrow R. Shotorbani, MBA, MT(ASCP)
President, and CEO, Project Santa Fe Foundation
9:15am – 9:45am: CL 2.0 Population Health and Acute Care - Unity/Volume of the Voices Amplifying the Movement: Future State Pathology and Clinical Lab Footprint
Speakers to be announced soon
9:45am – 10:15am: Q&A and Group Discussion
James Crawford, MD, PhD
Professor and Chair Emeritus, Department of Pathology and Laboratory Medicine, Northwell Health
NAVIGATING GOVERNMENT AFFAIRS AMIDST THE 'BURDEN OF THE PRESENT'
10:30am – 12pm: Transitioning Times: Policy - Fireside Chat
Achieving the Clinical Laboratory 2.0 vision of moving from a transactional relationship to a value driven business model that recognizes the laboratory as an invaluable healthcare asset requires engaging a broad range of stakeholders, including and perhaps especially, policy makers at the federal and state level. However, by necessity, government affairs work tends to predominantly focus on near-term regulatory and payment issues which are pertinent to and reinforce the current transactional Clinical Laboratory 1.0 state we live in. The challenge, then, is to determine how to respond to the needs of the present while also advocating for the public policies that will support a future in which clinical labs are driving better outcomes for patients, providers, and financial stakeholders, alike. In this session, our diverse panel will share ideas on what it will take for us to escape the ‘burden of the present’ and influence key government officials and agencies to assist in creating a better future.
Facilitator: William Morice II, MD, PhD
CEO, Mayo Clinical Laboratories
James Crawford, MD, PhD
Professor and Chair Emeritus, Department of Pathology and Laboratory Medicine, Northwell Health
Donald Karcher, MD, FCAP
President, CAP
Nancy Stratton, MBA
Chief Executive Officer, COLA
Susan Van Meter
President, ACLA
Q&A and Group Discussion
12pm – 1pm: Lunch
FOLLOWING THE MONEY: ALTERNATIVE PAYMENT
1pm – 2:30pm: Follow the Money: Traction for Change
How laboratory services are reimbursed is rapidly changing; by 2030, for example, all Medicare beneficiaries will have risk-based care contracts. While traditional lab testing reimbursement continues to decline, bonus and risk-based payments for managing disease are actually increasing – reporting an A1C value is now worth 1/50th of the value of identifying a diabetic in your population!
In this session, expert panelists will:
- Explain the dramatic increase in value-based care payments and what this shift means for labs.
- Discuss the market opportunity for laboratories in value-based care by providing concrete examples.
- Offer a toolkit for how labs can:
- evaluate their internal finances
- while leveraging longitudinal data, identify opportunities to close care gaps
- obtain payment for addressing those care gaps
Facilitator: Lena Chaihorsky
Senior Vice President, Payor Innovation, Alva10 Inc.
Renee Ennis, MBA, FHFMA
Former CFO, Rhodes Group, TriCore Reference Labs, Presbyterian Healthcare Services
Mark Fung, MD, PhD
Vice Chair for Population Health, University of Vermont Health Network
Roy Gandolfi, MD
Medical Director, Select Health/Intermountain Healthcare
Joseph Schulman
Senior Vice President, Value Based Strategy, Northwell Health
Glen Schuster
President, Chief Executive Officer, VedaPointe
Q&A and Group Discussion
2:30pm - 3pm: Closing Session - Call to Action
Octavia M. Peck Palmer, PhD
Vice Chair of Health Equity, Associate Professor of Pathology, University of Pittsburgh Medical Center